Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Cell Tissue Res ; 374(1): 137-148, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29869715

RESUMEN

The triggering receptor expressed by myeloid cells-1 (TREM-1) plays an important role in infectious and autoimmune diseases but how it contributes to ventilation-induced lung injury (VILI) and inflammation is unclear. Here, we examine the possibility that TREM-1 activates signaling dependent on Toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (Myd88) and nuclear factor (NF)-κB, which leads in turn to VILI. In a mouse model of VILI, which we validated based on lung edema and histopathology as well as cytokine levels, we examine mRNA and protein levels of TREM-1, TLR4, MyD88, NF-κB and its inhibitory protein I-κB in animals subjected to ventilation at normal or high tidal volume. The extent of lung edema, injury and inflammation were higher in the high tidal volume animals, as were the expression levels of all proteins examined. Treatment with TREM-1 agonist aggravated these effects, whereas treatment with TREM-1 antagonist attenuated them. Our results suggest that aggravation of VILI by TREM-1 in mice may be associated with TLR4-MyD88-NF-κB-dependent signaling.


Asunto(s)
Factor 88 de Diferenciación Mieloide/metabolismo , FN-kappa B/metabolismo , Neumonía/metabolismo , Receptor Toll-Like 4/metabolismo , Receptor Activador Expresado en Células Mieloides 1/metabolismo , Lesión Pulmonar Inducida por Ventilación Mecánica/metabolismo , Animales , Modelos Animales de Enfermedad , Masculino , Ratones , Neumonía/etiología , Neumonía/patología , Edema Pulmonar/etiología , Edema Pulmonar/metabolismo , Edema Pulmonar/patología , Respiración Artificial/efectos adversos , Transducción de Señal , Lesión Pulmonar Inducida por Ventilación Mecánica/patología
2.
J Int Med Res ; 45(3): 912-923, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28425829

RESUMEN

Background Dexmedetomidine (DEX), an α2-adrenergic receptor agonist, produces ideal sedation and early postoperative recovery for premedication in paediatric surgery, reducing preoperative anxiety and facilitating smooth induction of anaesthesia. We performed a meta-analysis to compare the effects of DEX and midazolam (MDZ) in paediatric anaesthesia with sevoflurane. Methods PubMed, Ovid, Web of Science, and Public Health Management Corporation were searched through December 2016 for randomized controlled trials (RCTs) that compared DEX and MDZ in children undergoing sevoflurane anaesthesia. The risk ratio (RR) with 95% incidence interval (95%CI) was used for dichotomous variables. Results Twelve RCTs involving 422 patients in the DEX group and 448 patients in the MDZ group were included. Patients in the DEX group had a significantly lower incidence of unsatisfactory sedation (RR [95%CI] = 0.71 [0.57-0.89]), unsatisfactory parental separation (RR [95%CI] = 0.56 [0.35-0.87]), and rescue analgesia (RR [95%CI] = 0.52 [0.35-0.77]) than patients in the MDZ group. However, both groups had a similar incidence of unsatisfactory mask acceptance, emergence agitation, and postoperative nausea and vomiting. Conclusion Compared with MDZ, DEX is beneficial in paediatric anaesthesia with sevoflurane because of its lower incidence of unsatisfactory sedation, parental separation, and rescue analgesia.


Asunto(s)
Dexmedetomidina/uso terapéutico , Hipnóticos y Sedantes/uso terapéutico , Éteres Metílicos/uso terapéutico , Midazolam/uso terapéutico , Niño , Dexmedetomidina/administración & dosificación , Humanos , Hipnóticos y Sedantes/administración & dosificación , Midazolam/administración & dosificación , Pediatría , Premedicación , Ensayos Clínicos Controlados Aleatorios como Asunto , Sevoflurano
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda